<SEC-DOCUMENT>0000950103-26-006498.txt : 20260430
<SEC-HEADER>0000950103-26-006498.hdr.sgml : 20260430
<ACCEPTANCE-DATETIME>20260430070504
ACCESSION NUMBER:		0000950103-26-006498
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260430
FILED AS OF DATE:		20260430
DATE AS OF CHANGE:		20260430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37891
		FILM NUMBER:		26920018

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp245993_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="border-top: Black 3pt solid; font-size: 1pt; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of April 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission file number: 001-37891</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AC IMMUNE SA </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EPFL Innovation Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Building B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1015 Lausanne, Switzerland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 30%">Form 20-F</TD>
    <TD STYLE="text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">Form 40-F</TD>
    <TD STYLE="text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 30, 2026, AC Immune SA issued a press release announcing that
it initiated the final cohort in the ongoing Phase 1b/2 ABATE trial of anti-Abeta active immunotherapy to treat Alzheimer&rsquo;s disease.
A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>



<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-top: 1pt; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center; width: 0.6in; padding-bottom: 1pt"><B>Exhibit<BR>
Number</B></TD>
    <TD STYLE="padding-top: 1pt; vertical-align: top; width: 0.2in; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; text-align: center; padding-bottom: 1pt"><A HREF="dp245993_ex9901.htm">99.1</A></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 1pt"><A HREF="dp245993_ex9901.htm">Press Release dated April 30, 2026</A></P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif"></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>AC IMMUNE SA</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%">/s/ Andrea Pfeifer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Andrea Pfeifer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Christopher Roberts</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Christopher Roberts</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Date: April 30, 2026</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp245993_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; width: 50%; font-size: 11pt; padding-left: 4pt"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 39px; width: 183px"></FONT></TD>
    <TD STYLE="padding-right: 4pt; width: 50%; text-align: right; font-size: 11pt; padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>PRESS
    RELEASE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AC Immune Initiates Final Cohort in Ongoing Phase
1b/2 ABATE <BR>
Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million
milestone payment</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Allows evaluation of potential for precision prevention of neurodegenerative
diseases</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Data from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected
Q2 2026</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Lausanne, Switzerland, April 30, 2026 -- </B>AC Immune SA (NASDAQ:
ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it
dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial. As a result, AC Immune will receive a $12 million milestone
payment from Takeda under the partners&rsquo; exclusive, worldwide option and license agreement for AC Immune&rsquo;s active immunotherapies
targeting toxic forms of amyloid beta (Abeta), including ACI-24 for the treatment of Alzheimer&rsquo;s disease (AD).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ABATE is assessing ACI-24 in subjects with prodromal AD and in adults
with Down syndrome (DS). AD4 includes subjects with prodromal AD.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Dr. Andrea Pfeifer, CEO of AC Immune SA</B>, said: &ldquo;This milestone
underscores the progress in our Phase 1b/2 ABATE trial of ACI-24. AD4 will build on the encouraging early safety and immunogenicity data
to date. It allows further evaluation of the potential of ACI-24 and, more broadly, our precision prevention approach to neurodegenerative
diseases, which encompasses a pipeline of active immunotherapies and intracellular-targeted small-molecule therapeutics to intervene at
the earliest stages of disease.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ACI-24 is an anti-Abeta active immunotherapy candidate designed to induce
a robust antibody response against the toxic forms of Abeta believed to drive plaque formation and AD progression. By inducing plaque
clearance and efficiently inhibiting plaque formation in the brain, ACI-24 has the potential to delay or slow AD progression.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ACI-24 is being investigated in the ongoing ABATE randomized, double-blind,
placebo-controlled Phase 1b/2 trial to assess its safety, tolerability, immunogenicity and pharmacodynamic effects. Data so far show that
ACI-24 is generally safe and well tolerated, and that it has generated anti-Abeta antibody responses at all tested doses.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Cohorts AD1, AD2 and AD3 enrolled a total of 74 patients who received
ACI-24 at escalating dose levels. The 12-month data readouts from Cohorts AD1, AD2 and AD3 are expected later in Q2 2026. Cohort AD4 will
include an initial group of 36 patients treated for 12 months, with follow-up of 6 months, significantly expanding the safety and biomarker
efficacy data set. A subsequent expansion of the AD4 cohort could potentially see the total number of subjects reach approximately 112
patients.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="padding-right: 4pt; font-size: 11pt; padding-left: 4pt; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 39px; width: 183px"></FONT></TD><TD STYLE="padding-right: 4pt; text-align: right; font-size: 11pt; padding-left: 4pt; width: 50%"><FONT STYLE="font-size: 10pt"><B>PRESS RELEASE</B></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">AC Immune is responsible for conducting the ABATE trial. Following the
potential option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory
activities as well as worldwide commercialization.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Under the terms of the agreement with Takeda, AC Immune received an
upfront payment of $100 million and is eligible to receive an option exercise fee and additional potential development, commercial and
sales-based milestones of up to approximately $2.1 billion, if all related milestones are achieved over the course of the agreement. Upon
commercialization, AC Immune will be entitled to receive tiered double-digit royalties on worldwide net sales.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>About ACI-24 </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">This product is AC Immune&rsquo;s anti-Abeta active immunotherapy candidate.
The ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial of ACI-24 for treatment of Alzheimer&rsquo;s disease (AD) continues
fully blinded (NCT05462106). Enrolled patients are required to have a diagnosis of prodromal AD: MCI due to AD according to the National
Institute on Aging Alzheimer&rsquo;s Association (NIA-AA) criteria, and a PET scan at screening must be consistent with the presence
of amyloid pathology. Patients will be randomized to one of several doses of ACI-24 or placebo. Following multiple data safety monitoring
board (DSMB) reviews, no safety concerns have been raised to date, consistent with previous results. Very encouraging immunogenicity
has been shown with clear evidence of anti-Abeta antibody responses against toxic Abeta species observed in the blinded data.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>About&nbsp;AC Immune SA&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">AC Immune SA is a clinical-stage biopharmaceutical company and a global
leader in precision prevention for neurodegenerative diseases, including Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease, and NeuroOrphan
indications driven by misfolded proteins. The Company&rsquo;s two clinically validated technology platforms, SupraAntigen&reg; and Morphomer&reg;,
fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including
candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global
pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$4.5 billion in potential
milestone payments plus royalties.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">SupraAntigen&reg; is a registered trademark of AC Immune SA in the following
territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer&reg; is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR,
NO, RU and SG.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The information on our website and any other websites referenced herein
is expressly not incorporated by reference into, and does not constitute a part of, this press release.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; font-size: 11pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>SVP,&nbsp;Investor
    Relations&nbsp;&amp; Corporate <BR>
    Communications<BR>
    <BR>
    </B>Gary Waanders, Ph.D., MBA<BR>
    AC Immune<BR>
    Phone: +41 21 345 91 91<BR>
    Email:&nbsp;<FONT STYLE="color: Blue"><U>gary.waanders@acimmune.com</U></FONT><B><BR>
    <BR></B></FONT></TD>
    <TD STYLE="width: 53%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>International Media<BR>
    <BR>
    </B>Chris Maggos<BR>
    Cohesion Bureau<BR>
    Phone: +41 79 367 6254<BR>
    Email:&nbsp;<FONT STYLE="color: Blue"><U>chris.maggos@cohesionbureau.com</U></FONT></FONT></TD>
    <TD STYLE="font-size: 11pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="padding-right: 4pt; font-size: 11pt; padding-left: 4pt; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 39px; width: 183px"></FONT></TD><TD STYLE="padding-right: 4pt; text-align: right; font-size: 11pt; padding-left: 4pt; width: 50%"><FONT STYLE="font-size: 10pt"><B>PRESS RELEASE</B></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Forward looking statements</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">This press release contains statements that constitute &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial
or business performance or AC Immune&rsquo;s strategies or expectations. In some cases, you can identify these statements by forward-looking
words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;projects,&rdquo; &ldquo;potential,&rdquo;
&ldquo;outlook&rdquo; or &ldquo;continue,&rdquo; and other comparable terminology. Forward-looking statements are based on management&rsquo;s
current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business
decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under
the captions &ldquo;Item 3. Key Information &ndash; Risk Factors&rdquo; and &ldquo;Item 5. Operating and Financial Review and Prospects&rdquo;
in AC Immune&rsquo;s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements
speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future
developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety
by this cautionary statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G +<# 2(  A$! Q$!_\0
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M?PFJ<=W+&NT-QVS7AU<<L-BYJJG9I6-E#FBK&LS!%+,< 5Y]XEO&N]7<?P1
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BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
